Featured Content

In Focus: Bendamustine for Non-Hodgkin Lymphomas

Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is ...

Hodgkin Lymphoma: Risk-adapted Therapy Recommended

Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.

More Features>>>

Video Series

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters